What is INAB's relative strength rating?

INAB ranks at the 36th percentile over 1 month, 14th percentile over 3 months, 22th percentile over 6 months, 16th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.

What sector is INAB in?

INAB is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data. Healthcare is currently ranked 3 of 11 sectors by relative strength.

Is INAB in a leading sector?

Yes — Healthcare ranks at the 82th percentile by sector relative strength, placing it in the leading band (≥ 70th percentile). INAB benefits from positive sector-level momentum, which historically correlates with above-average stock-level RS performance in the O'Neil / Minervini framework.

How volatile is INAB?

INAB currently shows a 20-day average daily range (ADR%) of 9.8%, a 90-day beta versus the S&P 500 of 0.90. An ADR% above 4% indicates an intraday swing-trading eligible name in the Minervini Volatility Contraction Pattern framework. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.

Does INAB have a seasonal pattern?

TickerStance computes INAB's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what INAB has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.

When did INAB last report earnings?

INAB most recently filed a 10-Q covering FY26 Q2 with the SEC on 2026-08-06. TickerStance sources earnings data from SEC EDGAR XBRL submissions and updates the fundamentals panel daily. The Pro dossier shows eight quarters of EPS and revenue trend, operating margin history, and a composite earnings-quality rank.

IN8bio, Inc. Common Stock (INAB) · RS 22

TODAY'S READ · AS OF 2026-08-24

As of 2026-08-24, IN8bio, Inc. Common Stock (INAB) has a 3-month relative strength percentile of 14 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 38. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 9.8%, relative volume 0.92×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.

RS methodology →

Market-wide RS; lit = leaderboard

Lenses lit

3 month14pctile

6 month22pctile

1 year16pctile

Classic14IBD pctile

LDR31leadership

0 of 5 lenses lit · avg RS pctile 19

✓ADR%9.8%!A/DC!RVOL0.92×!$ Vol$72K

COMPUTED · AS OF 2026-08-24

Pattern read

INAB is in a stage 4 downtrend, week 1. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -5.7% / -27.4%.

Pure factual computation. Not a recommendation. See stage analysis.

Market backdrop

47.8Neutral

Trend30% weight44.9 Breadth30% weight50.6 Leadership20% weight42.4 Macro20% weight59.0 Full stance breakdown →

Evidence · 1 of 3

Receipts behind the read

0 of 5 pass

Leadership

Is it leading?

Relative strength across horizons plus the leadership score.

1m

36

3m

14

6m

22

1y

16

LDR

—

StageWeinstein stage analysis

Stage 4 · Decline✓

Smart money

Who's accumulating?

Accumulation rating, relative volume, U/D ratio, breakout-day proof.

Fundamentals · INAB

Does the business back the chart?

SEC EDGAR · last filing 10-Q · FY26 Q2 · period end 2026-06-30

—

Fundamentals Growth Rank

How does growth rank vs. the universe?

EDGAR quarterly revenue basics absent: EPS quarterly facts present, no usable quarterly revenue series

View fundamental leadership map

Earnings

Are losses narrowing?

Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.

Loss narrowing

−$0.15—

24 Q3

−$0.03—

24 Q4

Evidence · 2 of 3

Sector context

Healthcare · 82th pctile in sector

Top peers · Healthcare

Who else is leading?

ELOX
99RS 3m
FBRX
99RS 3m
MRNA
99RS 3m
INAB
14RS 3m · you

Sector vs market

Healthcare · 3 of 11

Energy100

Technology91

Healthcare82

Financials

PEERS · Pharmaceutical Products

Same industry, closest relative strength

4 peers · by RS6M

AMPHAmphastar Pharmaceuticals, Inc.22 INSMInsmed, Inc.22 TYRATyra Biosciences, Inc. Common Stock23 DMACDiaMedica Therapeutics Inc. Common Stock23

§ Seasonality

10y · since 2022

Best monthMay on averageavg +26.38% · 60% win · n 5

Worst monthJun on averageavg -30.71% · 20% win · n 5

INAB monthly seasonality strip
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
1	INAB Jan avg: -5.69% median: -3.20% win: 0% σ: 7.18% n: 4 2022-04-12 → 2026-07-31	INAB Feb avg: -14.12% median: -14.16% win: 25% σ: 15.75% n: 4 2022-04-12 → 2026-07-31	INAB Mar avg: -14.99% median: -13.99% win: 25% σ: 18.27% n: 4 2022-04-12 → 2026-07-31	INAB Apr avg: -8.08% median: -0.68% win: 40% σ: 20.23% n: 5 2022-04-12 → 2026-07-31	INAB May avg: 26.38% median: 16.67% win: 60% σ: 48.64% n: 5 2022-04-12 → 2026-07-31	INAB Jun avg: -30.71% median: -28.87% win: 20% σ: 22.20% n: 5 2022-04-12 → 2026-07-31	INAB Jul avg: -7.29% median: -0.78% win: 40% σ: 16.93% n: 5 2022-04-12 → 2026-07-31	INAB Aug avg: -10.66% median: -4.52% win: 50% σ: 18.96% n: 4 2022-04-12 → 2026-07-31 (current)	INAB Sep avg: -18.37% median: -11.91% win: 0% σ: 22.44% n: 4 2022-04-12 → 2026-07-31	INAB Oct avg: -3.90% median: -4.62% win: 25% σ: 5.82% n: 4 2022-04-12 → 2026-07-31	INAB Nov avg: -3.95% median: -4.61% win: 50% σ: 11.05% n: 4 2022-04-12 → 2026-07-31	INAB Dec avg: 25.40% median: 25.47% win: 75% σ: 33.94% n: 4 2022-04-12 → 2026-07-31

Public attention · INAB

Is the crowd watching?

44/ 100 · vs its own 90-day norm▲ 0 vs 7dOverlooked

Weak relative strength and quiet attention. Little to read here either way.

Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.

News

Reference

Company snapshot

SectorHealthcare

IndustryPharmaceutical Products

SIC2836

Float7.0Mshares

Shares out9.9Mshares

Market cap$11.6MNano Cap

FAQ

Frequently asked questions

What is INAB's relative strength rating?: INAB ranks at the 36th percentile over 1 month, 14th percentile over 3 months, 22th percentile over 6 months, 16th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.
What sector is INAB in?: INAB is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data. Healthcare is currently ranked 3 of 11 sectors by relative strength.
Is INAB in a leading sector?: Yes — Healthcare ranks at the 82th percentile by sector relative strength, placing it in the leading band (≥ 70th percentile). INAB benefits from positive sector-level momentum, which historically correlates with above-average stock-level RS performance in the O'Neil / Minervini framework.
How volatile is INAB?: INAB currently shows a 20-day average daily range (ADR%) of 9.8%, a 90-day beta versus the S&P 500 of 0.90. An ADR% above 4% indicates an intraday swing-trading eligible name in the Minervini Volatility Contraction Pattern framework. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.
Does INAB have a seasonal pattern?: TickerStance computes INAB's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what INAB has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.

IN8bio, Inc. Common Stock (INAB) — Stance & relative strength

Lenses lit

Pattern read

Market backdrop

Receipts behind the read

Is it leading?

Who's accumulating?

Does the business back the chart?

Are losses narrowing?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

§ Seasonality

Is the crowd watching?

Company snapshot

Frequently asked questions

How much does it move?

Is revenue confirming?

Are margins expanding?

Share count: tailwind or headwind?

§ Seasonality

IN8bio, Inc. Common Stock (INAB) — Stance & relative strength

INAB is not confirmed as a leader. 14 is not yet a leadership-grade RS read, Market Stance is 47.8

Lenses lit

Pattern read

Market backdrop

Receipts behind the read

Is it leading?

Who's accumulating?

Does the business back the chart?

Are losses narrowing?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

Is the crowd watching?

Company snapshot

Frequently asked questions

How much does it move?

Is revenue confirming?

Are margins expanding?

Share count: tailwind or headwind?